Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006
- 1 October 2006
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (28) , e48
- https://doi.org/10.1200/jco.2006.08.4608
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Reversible Posterior Leukoencephalopathy Syndrome and BevacizumabNew England Journal of Medicine, 2006
- Reversible posterior leukoencephalopathy syndrome: a misnomer reviewedInternal Medicine Journal, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- A Reversible Posterior Leukoencephalopathy SyndromeNew England Journal of Medicine, 1996